French regulators report GMP failings at Anuh Pharma API processing plant

By Gareth Macdonald

- Last updated on GMT

Source: Anuh Pharma
Source: Anuh Pharma
Anuh Pharma has breached GMP rules at its API processing facility in Boisar, India say French regulators who visited the site last month.

According to a report​ published today, ANSM inspectors observed 24 deficiencies from good manufacturing practices (GMP) at the plant, which provides particle processing – micronization - services.

The major deviation was Anuh’s failure to pass details of its suppliers on to customers to which it sold processed active pharmaceutical ingredients (API).

The ANSM team also reported that azithromycin supplied to Europe labelled as being manufactured by Anuh was actually made by a non-compliant Chinese supplier called Hebei Dongfeng Pharmaceutical.

The inspectors also criticised Anuh’s document management practices after discovering several API repacking records and purchasing orders within a "pile of rubble on the other side of a wall​."

They wrote that: “The findings reveal a critical non-compliance of the quality system of the company as a whole. Moreover, due to the severe lack of transparency of the company regarding its manufacturing activities, there is no assurance as regards to the origin of every batch of active substances claimed to have been manufactured by the company at the Boisar site.

Consequently, it is considered that the identified risks are applicable to all active substances manufactured at the site​.”

GMP certificate

The inspectors also suggested that “withdrawal of current valid EU GMP certificate issued by the Agencia Italiana del Farmaco (IT/E/GMP/9/2013)​” be considered.

They also said: “The site has been issued a statement of non-compliance and active substances manufactured by the site should not be used for the manufacturing of medicinal products.”

The EDQM has yet to decide whether to withdraw CEPs issued to Anuh.

Related news

Show more

Related products

show more

Solution for challenging antibodies – Planova™ S20N

Solution for challenging antibodies – Planova™ S20N

Content provided by Asahi Kasei Medical Co., Ltd. | 24-Sep-2024 | White Paper

Designed as a next generation cellulose-based virus removal filter, Planova™ S20N has demonstrated robust filtration performance for challenging molecules...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Follow us

Products

View more

Webinars